You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Studies on small molecules.

From: Radiotherapy and "new" drugs-new side effects?

Substance Author(s) Year Study type N tumour RT dose/ChTx/technique Toxicity
Sunitinib Chi et al. [153] 2010 Phase II 23 HCC 52.5 (15 Fx) IMRT/3D-CT 9% grade III upper GI bleeding, 4% hepatitis grade III/4% grade III pancreatitis, 26% grade III + IV thrombopenia, 4% grade III leukopenia
  Stähler et al. [154] 2010 Prospective, non-randomized 22 RCC (all sites) Median 40 Gy (median 8 Fx) 5% grade IV hypertension, 14% grade III + IV nausea
  Kao et al. [80] 2009 Phase I 21 Oligometastases 40-50 Gy (10 Fx) 62% grade III + IV lymphopenia, 19% grade III neutropenia, 14% grade III + IV thrombopenia, 5% grade III rectal bleeding
  Hui et al. [155] 2010 Phase II 13 Nasopharyngeal carcinoma Sunitinib after RT (60-70 Gy) and multiple Chx 15% fatal hemorrhages, 31% Grade IV hemorrhages, (among other toxicities)
sorafenib Peters et al. [77] 2008 Case study 1 RCC 8 Gy single dose Grade V bowel perforation (stopped two days before, three days later recommenced)
lapatinib Harrington et al. [156] 2009 Phase I 31 LA-HNSCC 66-70 Gy + CisPt 35% grade III mucositis, 19% grade III dermatitis, 13% grade III + IV lymphopenia, 6% grade III neutropenia
gefitinib Cohen et al. [157] 2010 Phase I 69 LA-HNSCC IC Carbo/Tax, hydroxyurea + 5-FU, 2 × 1.5 Gy/d 29% grade III + IV neutropenia, 86% grade III + IV mucositis, 33% grade III + IV dermatitis, 3% grade V infections, 17% grade III + IV infections, 4% grade III rash, 3% grade III neurotoxicity
  Pollack et al. [158] 2011 Phase II 43 Brainstem glioma in children 55,8 Gy Grade III+IV: lymphopenia (21%), neutropenia (2%), GI (12%), infection (7%), n, pulmonary (5%), renal, skin (2%), metabolic (2%), intratumoral hemorrhage: 7%.
  Valentini et al. [159] 2008 Phase I/II 41 Rectal cancer 45 Gy + 5.4 Gy + 5-FU 20% grade III + IV GI toxicity, 15% grade III + IV skin toxicity, 39% grade III + IV hepatic toxicity, 10% grade III + IV GU toxicity, 7% other toxicities grade III + IV
  Wang et al. [160] 2011 Prospective 26 Stage III/IV NSCLC Median 70 Gy Grade IV leukopenia 4%, grade IV thrombopenia 8%, grade III esophagitis 4%, grade III pneumonitis 4%
  Zhang et al. [161] 2009 Phase I 24 NSCLC 54-60 Gy 4% grade III nausea
  Chen et al. [162] 2007 Phase I 23 HNSCC Up to 72 Gy 13% grade III dermatitis, 57% grade III + IV mucositis, 39% grade III + IV dysphagia, 17% grade III + IV diarrhea, 30% grade III + IV neutropenia, 9% grade III + IV anemia, 4% grade IV tumour hemorrhage, 4% grade III GI bleeding
  Maurel et al. [163] 2006 Phase I 18 Pancreatic cancer 45 Gy No DLT, 11% grade III + IV neutropenia, 6% anemia grade III
  Czito et al. [164] 2006 Phase I 16 Pancreatic + rectal cancer 50.4 Gy (1.8 Gy) + capecitabine 31% grade III + IV diarrhea
  Center et al. [165] 2010 Phase I 16 NSCLC 70 Gy 3D-CT + docetaxel 27% grade III + IV hematotoxicity, 27% grade III + IV esophagitis, 20% grade III + IV pulmonary toxicity
  Schwer et al. [166] 2008 Phase I 15 Malignant glioma SRS 18-36 Gy No DLT, no grade > II
  Olsen et al. [167] 2009 Phase I 12 Pancreatic cancer 50.4 Gy (1.8 Gy) 45% grade III nausea
erlotinib Brown et al. [168] 2008 Phase I/II 79 GBM 60 Gy + TMZ 18% grade III/IV rash, 16% grade III/IV fatigue, 24% grade III/IV thrombopenia, 4% grade III nausea, 8% grade III diarrhea, 28% grade III/IV leukopenia, 3% grade III anorexia, 18% grade III/IV neutropenia, 6% grade III anemia, 14% grade III lymphopenia, 1% grade V infection without neutropenia, 5% grade III infection without neutropenia, 6% grade III/IV dyspnea, 1% grade III/IV keratitis, 1% grade V pneumonitis, 6% grade III/IV pneumonitis
  Prados et al. [169] 2009 Phase II 65 GBM 59.4 Gy/60 Gy + TMZ 43% grade III lymphopenia, 3% grade IV neutropenia, 2% grade IV thrombopenia, 8% grade III/IV fatigue, 2% grade III diarrhea, 6% grade III rash
  Herchenhorn et al. [170] 2010 Phase I/II 37 LA-HNSCC 70 Gy + Cis No DLT
  Choong et al. [171] 2008 Phase I 34 NSCLC Stage III 66 Gy (2 Gy), Arm A: Erlotinib + Cis/Eto, Arm B: Induction Carbo/Tax, Carbo/Tax + Erlotinib 41% grade III + IV WBC, 32% grade III + IV neutropenia, 21% grade III + IV thrombopenia, 26% grade III + IV esophagitis, 3% grade III + IV vomiting, 6% grade III + IV diarrhea, 3% grade III/IV pneumonitis/ototoxicity
  Peereboom et al. [172] 2010 Phase II 27 GBM 60 Gy + TMZ 7% grade V febrile neutropenia, 4% grade V sepsis without neutropenia, 4% grade V PCP, a pt grade III neutropenia, 15% grade III neutropenia, 30% grade III + IV thrombopenia, 56% pts grade III lymphopenia, 15% grade III + IV anemia, 7% grade III fatigue
  Chang et al. [173] 2011 Retrospective 25 NSCLC 40-50 Gy 4% grade III rash, 4% grade III diarrhea/esophagitis/anemia, 8% grade III neutropenia/thrombopenia, 8% grade V pneumonitis, 4% grade III pneumonitis
  Li et al. [174] 2010 Phase II 24 LA esophageal cancer 60 Gy + Carbo/Tax 17% ≥ grade III leukopenia, 8% thrombopenia ≥ grade III
  Broniscer et al. [175] 2009 Phase I 23 GBM 54-59.4 Gy 39% grade III + IV lymphopenia, 4% grade III rash, 4% grade III diarrhea
  Robertson et al. [176] 2009 Phase I 22 Pancreatic cancer Gem weekly, 30-38 Gy 5% grade III vomiting/fatigue/nausea, 5% grade III vomiting/diarrhea/nausea, 9% grade IV fatigue
  Duffy et al. [177] 2008 Phase I 20 Pancreatic cancer 50.4 Gy + Gem 100% grade III lymphopenia, 25% grade III thrombopenia, 30% grade III neutropenia, 5% grade IV neutropenia, 10% grade III anemia, 5% grade III fatigue, 15% grade III diarrhea, 10% grade III rash
  Krishnan et al. [178] 2006 Phase I 20 GBM 60 Gy 15% grade III stomatitis, 5% grade III fatigue/diarrhea
  Iannitti et al. [179] 2005 Phase I 17 LA Pancreatic cancer 50.4 Gy + Tax/Gem 6% grade III nausea/fatigue/rash/small bowel stricture/thrombopenia (each), 18% grade III dehydration/thrombosis, 12% grade III diarrhea/hypersensitivity, 6% grade IV neutropenia
  Nogueira-Rodrigues et al. [180] 2008 Phase I 15 LA cervical cancer 45 Gy + brachyTx + CisPt 7% grade IV hepatotoxicity, 7% grade III dermatitis, 20% III diarrhea, 13% grade III rash
  Arias de la Vega et al. [181] 2011 Phase I 13 LA-HNSCC 63 Gy + Cis adjuvant Grade III/IV: Mucositis 54%, Asthenia 15%, skin 23%, diarrhea 15%.
  Lind et al. [182] 2009 Phase I 11 NSCLC, brain metastases WBRT (30 Gy) 9% grade III rash/fatigue
  Dobelbower et al. [183] 2006 Phase I 11 Esophageal cancer 50.4 Gy + 5-FU 36% pts grade III + IV leukopenia, 9% grade III anemia, 9% grade III thrombopenia, 18% grade III + IV neutropenia, 27% grade III dehydration, 9% grade III nausea, 9% grade III/9% grade IV esophagitis
  Silvano et al. [82] 2008 Case report 1 NSCLC 2 × 8 Gy Death caused by fatal diarrhea
  Huang et al. [184] 2008 Case study 1 NSCLC WBRT 37.5 Gy Death caused by exacerbated radiodermatitis and subdural hemorrhage
mTOR inhibitors (Sirolimus) Sarkaria et al. [185] 2007 Phase I 7 NSCLC 60 Gy + CisPt weekly 14% grade III dysphagia, esophagitis, febrile neutropenia, pneumonia
  Bourgier et al. [186] 2011 Case reports 3 Breast/prostate/ovary cancer 45 Gy/70 Gy, later Gastrointestinal radiation recall syndrome with everolimus/temsirolimus
  1. N-number of patients, pt(s)-patient(s), n. r.-not reported, ChTx-chemotherapy, HCC-hepatocellular carcinoma, RCC-renal cell cancer, GBM-glioblastoma multiforme, DVT-deep vein thrombosis, Fx-fractions, SRS-stereotactic radiosurgery, DLT-dose limiting toxicity, LA-locally advanced, Gem-gemcitabine, Tax-Taxol (paclitaxel), Tx-therapy, TMZ-temozolomide, PCP-Pneumocystis pneumonia, Cis-cisplatin, Eto-etoposide,